INTENSITY THERAPEUTICS, INC. (INTS) Earnings History

INTENSITY THERAPEUTICS, INC. - Q3 2025 EarningsMissed

Filed at: Nov 5, 2025, 7:00 PM EST|Read from source

EXECUTIVE SUMMARY

Intensity Therapeutics reported its third quarter 2025 results, highlighting progress in its clinical trials and significant capital raises that extend its cash runway. The company is preparing to amend its INVINCIBLE-4 study protocol and reinitiate patient enrollment in early 2026, while also celebrating the publication of its IT-01 study manuscript in a Lancet Discovery Science journal.

POSITIVE HIGHLIGHTS

  • •

    Cash runway extended until the end of the first quarter of 2027 due to $13.6 million in gross proceeds raised since the beginning of Q3 2025.

    positive
  • •

    IT-01 Study manuscript published in eBioMedicine (Lancet Discovery Science journal), showing a disease control rate of 75% and median overall survival of 11.9 months in advanced solid tumors.

    positive
  • •

    INVINCIBLE-4 Study protocol amendment expected in Q1 2026 to revise dosing regimen, with patient enrollment expected to reinitiate in Q1 2026.

    positive
  • •

    Net loss decreased to $2.7 million for Q3 2025 from $3.5 million in Q3 2024.

    positive

CONCERNS & RISKS

  • •

    New patient enrollment in the INVINCIBLE-4 Study was paused in September 2025 due to localized skin irritation near the tumor site in some patients.

    attention
  • •

    New site activations and patient enrollments in the INVINCIBLE-3 Study were paused in March 2025 due to funding constraints.

    attention
  • •

    Loss from operations was $2.7 million for Q3 2025, and $8.8 million for the nine months ended September 30, 2025.

    negative
  • •

    Loss per share was $(0.06) for Q3 2025 and $(0.33) for the nine months ended September 30, 2025.

    negative

FINANCIAL METRICS

Revenue
Quarterly
N/A
N/A
Net Income
Quarterly
$-2.67M
+23.4%
Prior year: $-3.51M
Annual (YTD)
$-8.55M
N/A
Prior year: $-13.09M
EPS (Diluted)
Quarterly
$-0.06
+76.0%
Prior year: $-0.25
Operating Income
Quarterly
$-2.73M
+23.4%
Prior year: $-3.57M
Annual (YTD)
$-8.83M
N/A
Prior year: $-13.38M
EPS (Basic)
Quarterly
$-0.06
+76.0%
Prior year: $-0.25

MARGIN ANALYSIS

Margin metrics will be available once backend extracts data from insights_json

MANAGEMENT COMMENTARY

Substantially improved balance sheet with multiple fundraising transactions.

— INTENSITY THERAPEUTICS, INC., Q3 2025 2025 Earnings Call

New capital raised enables execution of business strategy until end of Q1 2027.

— INTENSITY THERAPEUTICS, INC., Q3 2025 2025 Earnings Call

Peer-reviewed paper in eBioMedicine provides validation of INT230-6 potential.

— INTENSITY THERAPEUTICS, INC., Q3 2025 2025 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.

OPERATIONAL METRICS

General and administrative
1.2M
-16.8% YoY
Prior year: 1.4M
dollars
Research and development
1.6M
-27.3% YoY
Prior year: 2.2M
dollars
Total operating expenses
2.7M
-23.4% YoY
Prior year: 3.6M
dollars

Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.